Gene Regulation Laboratories is a biotechnology company developing designer drugs - small molecule therapeutics for serious blood diseases and cancer conditions which have no definitive therapies now. Therapeutics activate beneficial genes or induce programmed cell death of cancer cells. Successful Phase II clinical trials were completed in 3 disease arenas. Pursuing rapid drug approval strategies, first in orphan patient populations, or rapid approval with available animal efficacy, and safety trials in normal humans, for an oral radiation protectant drug. Follow-on expansion into larger global markets is planned for multiple medical conditions
